EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
| Autor: | McCarthy, G, Baluni, G, Chhabra, N, Bhadra, D, Xu, R, Chaudhuri, M, Massaad, R, Amonkar, M |
|---|---|
| Zdroj: | In Value in Health June 2024 27(6) Supplement:S121-S122 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect